SELLAS Life Sciences Group, Inc. – NASDAQ:SLS
Founder-led company
SELLAS Life Sciences Group stock price today
$1.71
+0.72
+74.44%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
SELLAS Life Sciences Group stock price monthly change
-15.52%
month
SELLAS Life Sciences Group stock price quarterly change
-15.52%
quarter
SELLAS Life Sciences Group stock price yearly change
-6.67%
year
SELLAS Life Sciences Group key metrics
Market Cap | 62.66M |
Enterprise value | 14.27M |
P/E | -0.77 |
EV/Sales | 14.27 |
EV/EBITDA | -0.21 |
Price/Sales | 30.45 |
Price/Book | 6.27 |
PEG ratio | -0.04 |
EPS | -1.1 |
Revenue | N/A |
EBITDA | -26.78M |
Income | -35.80M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -6645.9% |
Oper. margin | -6730.8% |
Gross margin | 80% |
EBIT margin | -6730.8% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSELLAS Life Sciences Group stock price history
SELLAS Life Sciences Group stock forecast
SELLAS Life Sciences Group financial statements
| Jun 2023 | 0 | -8.84M | |
|---|---|---|---|
| Sep 2023 | 0 | -9.26M | |
| Dec 2023 | 0 | -8.13M | |
| Mar 2024 | 0 | -9.56M |
| Dec 2023 | 0 | -8.13M | |
|---|---|---|---|
| Mar 2024 | 0 | -9.56M | |
| Sep 2025 | 0 | -5.37M | |
| Dec 2025 | 0 | -5.37M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 18566000 | 13.72M | 73.91% |
|---|---|---|---|
| Sep 2023 | 8086000 | 11.91M | 147.33% |
| Dec 2023 | 6403000 | 14.37M | 224.57% |
| Mar 2024 | 24434000 | 14.75M | 60.37% |
| Jun 2023 | -7.56M | -2.5M | -29K |
|---|---|---|---|
| Sep 2023 | -6.89M | -3M | 54K |
| Dec 2023 | -4.82M | 0 | 3.38M |
| Mar 2024 | -10.76M | 0 | 26.64M |
SELLAS Life Sciences Group alternative data
| Aug 2023 | 17 |
|---|---|
| Sep 2023 | 17 |
| Oct 2023 | 17 |
| Nov 2023 | 17 |
| Dec 2023 | 17 |
| Jan 2024 | 17 |
| Feb 2024 | 17 |
| Mar 2024 | 17 |
| Apr 2024 | 17 |
| May 2024 | 16 |
| Jun 2024 | 16 |
| Jul 2024 | 16 |
SELLAS Life Sciences Group other data
11.27%
+2.09%
of SLS is owned by hedge funds
13
-14
2.18M
+297.27K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2022 | 0 | 9806 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | STERGIOU ANGELOS M. director, officer: President an.. | Class A Common Stock | 6,494 | $2.61 | $16,936 | ||
Sale | WOOD BARBARA A officer: EVP, Gen.. | Class A Common Stock | 2,153 | $2.59 | $5,576 | ||
Sale | BURNS JOHN THOMAS officer: Senior VP, Finance & CAO | Class A Common Stock | 1,159 | $2.59 | $3,002 | ||
Sale | BURNS JOHN THOMAS officer: VP, Finance & Corp Con.. | Common Stock | 231 | $6.27 | $1,448 | ||
Sale | WOOD BARBARA A officer: EVP, Gen.. | Common Stock | 847 | $6.26 | $5,298 | ||
Sale | STERGIOU ANGELOS M. director, officer: President an.. | Common Stock | 2,120 | $6.25 | $13,252 | ||
Sale | STERGIOU ANGELOS M. director, officer: President an.. | Common Stock | 23,277 | N/A | N/A | ||
Sale | NISI RUDOLPH director | Common Stock | 500 | N/A | N/A | ||
Purchase | HUDSON BAY CAPITAL MANAGEMENT LP 10 percent owner | Call Options (obligation to sell) | 1,100 | N/A | N/A | ||
Sale | HUDSON BAY CAPITAL MANAGEMENT LP 10 percent owner | Common Stock, par value $0.001 per share ("Common Stock") | 2,363,441 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q3 2018 15 Nov 2018 | Q3 2018 Earnings Call Transcript |
| Q3 2016 10 Nov 2016 | Q3 2016 Earnings Call Transcript |
| Q2 2016 10 Aug 2016 | Q2 2016 Earnings Call Transcript |
| Q1 2016 11 May 2016 | Q1 2016 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Angelos M. Stergiou M.D., ScD h.c. (1976) Founder, Pres, Chief Executive Officer & Director | $827,570 |
| Ms. Barbara A. Wood (1963) Executive Vice President, Gen. Counsel & Sec. | $577,290 |
| Dr. Dragan Cicic (1963) Senior Vice President of Clinical Devel. | $435,430 |
-
What's the price of SELLAS Life Sciences Group stock today?
One share of SELLAS Life Sciences Group stock can currently be purchased for approximately $1.71.
-
When is SELLAS Life Sciences Group's next earnings date?
Unfortunately, SELLAS Life Sciences Group's (SLS) next earnings date is currently unknown.
-
Does SELLAS Life Sciences Group pay dividends?
No, SELLAS Life Sciences Group does not pay dividends.
-
How much money does SELLAS Life Sciences Group make?
SELLAS Life Sciences Group has a market capitalization of 62.66M.
-
What is SELLAS Life Sciences Group's stock symbol?
SELLAS Life Sciences Group, Inc. is traded on the NASDAQ under the ticker symbol "SLS".
-
What is SELLAS Life Sciences Group's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of SELLAS Life Sciences Group?
Shares of SELLAS Life Sciences Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are SELLAS Life Sciences Group's key executives?
SELLAS Life Sciences Group's management team includes the following people:
- Dr. Angelos M. Stergiou M.D., ScD h.c. Founder, Pres, Chief Executive Officer & Director(age: 49, pay: $827,570)
- Ms. Barbara A. Wood Executive Vice President, Gen. Counsel & Sec.(age: 62, pay: $577,290)
- Dr. Dragan Cicic Senior Vice President of Clinical Devel.(age: 62, pay: $435,430)
-
Is SELLAS Life Sciences Group founder-led company?
Yes, SELLAS Life Sciences Group is a company led by its founder Dr. Angelos M. Stergiou M.D., ScD h.c..
-
How many employees does SELLAS Life Sciences Group have?
As Jul 2024, SELLAS Life Sciences Group employs 16 workers, which is 6% less then previous quarter.
-
When SELLAS Life Sciences Group went public?
SELLAS Life Sciences Group, Inc. is publicly traded company for more then 17 years since IPO on 12 Mar 2008.
-
What is SELLAS Life Sciences Group's official website?
The official website for SELLAS Life Sciences Group is sellaslifesciences.com.
-
Where are SELLAS Life Sciences Group's headquarters?
SELLAS Life Sciences Group is headquartered at Times Square Tower, New York, NY.
-
How can i contact SELLAS Life Sciences Group?
SELLAS Life Sciences Group's mailing address is Times Square Tower, New York, NY and company can be reached via phone at +64 6 200 5278.
SELLAS Life Sciences Group company profile:
SELLAS Life Sciences Group, Inc.
sellaslifesciences.comExchange:
NASDAQ
Full time employees:
16
Industry:
Biotechnology
Sector:
Healthcare
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Times Square Tower
New York, NY 10036
New York, NY 10036
CIK: 0001390478
ISIN: US81642T2096
CUSIP: 81642T209
